Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases

Sponsor
Sun Yat-sen University
Study ID
NCT06265350
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Cadonilimab — DRUG
    Cadonilimab, 375mg，Q3W， IV
  • Bevacizumab — DRUG
    Bevacizumab, 7.5mg/kg，Q3W， IV
  • Cryoablation — PROCEDURE
    Patients accepted Cryoablation of pulmanary metastases

Study Details

This study intends to evaluate the efficacy and safety of cryoablation combined with Cardonilizumab and Bevacizumab in hepatocellular carcinoma with pulmonary metastases.

Key Dates

First listed
Feb 20, 2024
Start date
Feb 2, 2024
Status verified
Feb 2024
Primary completion
Jan 30, 2026
Completion
Jan 30, 2027

Study Design

Enrollment
80 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Bevacizumab+Cadonilimab group
    Patients accepted Bevacizumab (7.5mg/kg，Q3W， IV) plus Cadonilimab (375mg，Q3W， IV)
  • Experimental: Cryoablation+Bevacizumab+Cadonilimab
    Patients accepted Cryoablation of pulmanary metastases combined with Bevacizumab (7.5mg/kg，Q3W， IV) and Cadonilimab (375mg，Q3W， IV)

Primary Outcome Measure

Objective response rate (ORR) [ Time Frame: 6 months ]

Central Contacts

Related Studies